circATAD2 mitigates CD8+ T cells antitumor immune surveillance in breast cancer via IGF2BP3/m6A/PD-L1 manner
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03705-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Zhiling Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Shanxi Provincial People's Hospital, Taiyuan, 030012, China. zhangzhilingpro@sina.com. Hauptthemen laut MEDLINE: B7-H1 Antigen, Breast Neoplasms, CD8-Positive T-Lymphocytes, Immunologic Surveillance. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune surveillance and chemotherapy sensitivity play critical functions in the tumorigenesis of breast cancer (BC). Emerging findings have indicated that circular RNA (circRNA) and N 6 -methyladenosine (m 6 A) both participate in the BC tumorigenesis. Here, present study aimed to investigate the roles of m 6 A-modified circATAD2 on BC and explore better understanding for BC precision therapeutic. Results reported that m 6 A-modifid circRNA (m 6 A-circRNA) microarray revealed the m 6 A-circRNA landscape in BC. M 6 A-modifid circATAD2 upregulated in BC samples and was closely correlated to poor prognosis. Functionally, circATAD2 promoted the immune evasion of BC cells and reduced the CD8 + T cells’ killing effect. Mechanistically, MeRIP-seq unveiled the m 6 A modification in the 3’-UTR of PD-L1 mRNA, which was bound by circATAD2 and recognized by m 6 A reader IGF2BP3 to enhance PD-L1 mRNA stability and expression. In summary, these findings revealed the circATAD2/m 6 A/IGF2BP3/PD-L1 axis in BC immune surveillance, suggesting the potential that circATAD2 as a potential target for PD-L1-mediated BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Shanxi Provincial People's Hospital, Taiyuan, 030012, China. zhangzhilingpro@sina.com.
- Department of Breast Surgery, Shanxi Provincial People's Hospital, Taiyuan, 030012, China.
Zitieren
APA
Zhang, Z., Huo, W., & Li, J. (2024). circATAD2 mitigates CD8+ T cells antitumor immune surveillance in breast cancer via IGF2BP3/m6A/PD-L1 manner. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03705-6
Vancouver
Zhang Z, Huo W, Li J. circATAD2 mitigates CD8+ T cells antitumor immune surveillance in breast cancer via IGF2BP3/m6A/PD-L1 manner. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03705-6
BibTeX
@article{Zhang2024,
author = {Zhang, Zhiling and Huo, Wenjie and Li, Jie},
title = {circATAD2 mitigates CD8+ T cells antitumor immune surveillance in breast cancer via IGF2BP3/m6A/PD-L1 manner},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03705-6}
}
EUVIMED